help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vitte, C.
Right arrow Articles by Guenther, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vitte, C.
Right arrow Articles by Guenther, H. L.

Endocrinology, Vol 137, 2324-2333, Copyright © 1996 by Endocrine Society

ARTICLES

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

C Vitte, H Fleisch and HL Guenther
Department of Pathophysiology, University of Berne, Switzerland.

Current knowledge indicates that osteoblasts play an integral role in osteoclastic bone resorption through an osteoclast-stimulating activity produced by osteoblasts in response to resorption-promoting osteotropic factors. Previously, we have shown that the inhibitory action of the bisphosphonates on bone resorption in part is mediated by osteoblasts. The aim of the present study was to investigate whether the bisphosphonate-generated inhibition is due to these compounds decreasing the synthesis of the osteoclast-stimulating activity or is the result of osteoblasts synthesizing an osteoclast resorption inhibitor. Using the osteoblastic cell line CRP 10/30, which produces osteoclast- stimulating activity, constitutively and employing isolated rat osteoclasts cultured on ivory, evidence was obtained indicating that the bisphosphonates ibandronate and alendronate at a concentration of 10(-7) M induce osteoblasts to synthesize an osteoclast inhibitor that reduces pit formation by more than 50%. The inhibitor is heat and proteinase labile and has a molecular mass between 1-10 kDa. The reduction of resorption pits is paralleled by a decrease in tartrate- resistant acid phosphatase-positive mono- and multinucleated cells, whereas the mean area resorbed per pit was not changed, suggesting that the inhibitor affects osteoclast formation and/or survival and probably not the osteoclast resorption activity. Rat preosteoblastic cells and rat dermal fibroblasts were found not to produce the inhibitor. In conclusion, osteoblasts aside from their role of mediating osteoclastic resorption promoters are also involved in inhibiting bone resorption through the synthesis of an osteoclast resorption inhibitor.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
S.-B. Woo, J. W. Hellstein, and J. R. Kalmar
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Ann Intern Med, May 16, 2006; 144(10): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
R. G. G. RUSSELL
Bisphosphonates: From Bench to Bedside
Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 367 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
M. R. MARKIEWICZ, J. E. MARGARONE III, J. H. CAMPBELL, and A. AGUIRRE
Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge
J Am Dent Assoc, December 1, 2005; 136(12): 1669 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
K. Suzuki, S. Takeyama, T. Kikuchi, S. Yamada, J. Sodek, and H. Shinoda
Osteoclast Responses to Lipopolysaccharide, Parathyroid Hormone and Bisphosphonates in Neonatal Murine Calvaria Analyzed by Laser Scanning Confocal Microscopy
J. Histochem. Cytochem., December 1, 2005; 53(12): 1525 - 1537.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Ann. Onc., October 1, 2003; 14(10): 1468 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. GROTZ, C. NAGEL, D. POESCHEL, M. CYBULLA, K.-G. PETERSEN, M. UHL, C. STREY, G. KIRSTE, M. OLSCHEWSKI, A. REICHELT, et al.
Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation
J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1530 - 1537.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. V. Lee, E. M. Fong, F. R. Singer, and R. S. Guenette
Bisphosphonate Treatment Inhibits the Growth of Prostate Cancer Cells
Cancer Res., March 1, 2001; 61(6): 2602 - 2608.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
G. G. Reinholz, B. Getz, L. Pederson, E. S. Sanders, M. Subramaniam, J. N. Ingle, and T. C. Spelsberg
Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts
Cancer Res., November 1, 2000; 60(21): 6001 - 6007.
[Abstract] [Full Text]

Home page
 CLIN PEDIATRHome page
T. Srivastava and U. S. Alon
Bisphosphonates: From Grandparents to Grandchildren
Clinical Pediatrics, November 1, 1999; 38(12): 687 - 702.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
A. Sabokbar, Y. Fujikawa, D. W Murray, and N. A Athanasou
Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption
Ann Rheum Dis, October 1, 1998; 57(10): 614 - 618.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
H. Fleisch
Bisphosphonates: Mechanisms of Action
Endocr. Rev., February 1, 1998; 19(1): 80 - 100.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society